HNB
CRSP icon

Huntington National Bank’s CRISPR Therapeutics CRSP Stock Holding History

Huntington National Bank’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17
Closed -$579 – 4169
2025
Q1 		$579 Hold
17
– – ﹤0.01% 2442
2024
Q4 		$669 Sell
17
-287
-94% -$13.6K ﹤0.01% 2455
2024
Q3 		$14.3K Hold
304
– – ﹤0.01% 1626
2024
Q2 		$16.4K Hold
304
– – ﹤0.01% 1524
2024
Q1 		$20.7K Hold
304
– – ﹤0.01% 1448
2023
Q4 		$19K Buy
304
+34
+13% +$1.88K ﹤0.01% 1430
2023
Q3 		$12.3K Hold
270
– – ﹤0.01% 1499
2023
Q2 		$15.2K Hold
270
– – ﹤0.01% 1447
2023
Q1 		$12.2K Sell
270
-15
-5% -$729 ﹤0.01% 1472
2022
Q4 		$11.6K Sell
285
-5
-2% -$265 ﹤0.01% 1448
2022
Q3 		$19K Hold
290
– – ﹤0.01% 1305
2022
Q2 		$17K Hold
290
– – ﹤0.01% 1388
2022
Q1 		$18K Hold
290
– – ﹤0.01% 1403
2021
Q4 		$22K Hold
290
– – ﹤0.01% 1343
2021
Q3 		$32K Sell
290
-160
-36% -$20.1K ﹤0.01% 1095
2021
Q2 		$73K Buy
450
+160
+55% +$19.5K ﹤0.01% 827
2021
Q1 		$35K Hold
290
– – ﹤0.01% 942
2020
Q4 		$44K Buy
290
+90
+45% +$10.6K ﹤0.01% 858
2020
Q3 		$17K Hold
200
– – ﹤0.01% 1100
2020
Q2 		$15K Buy
+200
New +$11.7K ﹤0.01% 1117

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Huntington National Bank's CRSP Position: Q2 2025 in Review

Huntington National Bank sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 17 shares — an estimated $579 sold.

Huntington National Bank first reported a position in CRSP in Q2 2020 and held it in 20 quarters. The position peaked at $73K in Q2 2021. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

  • Huntington National Bank reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Huntington National Bank sold 17 CRISPR Therapeutics shares in Q2 2025, an estimated $579.
  • Huntington National Bank first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 20 quarters.
  • Huntington National Bank's CRISPR Therapeutics position peaked at $73K in Q2 2021.
  • 433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Huntington National Bank's 13F filing for Q2 2025, filed 5 Aug 2025.